On March 10, 2022 Seneca Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of targeted oncolytic immunotherapeutics based on Seneca Valley Virus (SVV-001), reported that it will host a key opinion leader (KOL) webinar titled "Seneca Valley Virus and TEM8" on Wednesday, March 16, 2022 at 2:00pm Eastern Time (Press release, Seneca Therapeutics, MAR 10, 2022, View Source [SID1234609919]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The webinar will feature presentations from cancer researcher Mihnea Bostina, Ph.D., from the University of Otago and cancer clinician Aman Chauhan, M.D., from the University of Kentucky. Dr. Bostina will discuss the unique characteristics and exquisite solid tumor specificity of SVV-001 in the treatment of solid cancers. He will also discuss the mechanism of SVV receptor selectivity, specifically TEM8, an integrin expressed primarily on the surface of solid tumor cells. In multiple, well controlled clinical trials, TEM8 was shown to be an important adverse prognostic indicator of survival of patients with a variety of solid tumors. Dr. Chauhan will review three prior human clinical trials performed with intravenously delivered SVV-001 to patients having one of several solid cancer indications. He will also present new data on SVV’s profound ability to synergize with checkpoint inhibitors in animal models. Dr. Chauhan will discuss the Company’s upcoming Phase I/II randomized trial design in patients with neuroendocrine neoplasms that have SVV-001 sensitivity based on the SVV Companion Diagnostic.

Dr. Paul Hallenbeck, President and Chief Scientific Officer at Seneca Therapeutics will give a brief presentation on the history of SVV-001. He will also discuss two new programs in development including the enablement of multiple intravenous administration with SVV and a significant pipeline of armed SVV constructs.

A live question-and-answer session will follow. To register for the event, please click here.